XSHE
300439
Market cap470mUSD
Jul 10, Last price
8.46CNY
1D
1.81%
1Q
-14.02%
Jan 2017
-71.98%
IPO
-41.74%
Name
MedicalSystem Biotechnology Co Ltd
Chart & Performance
P/E
51.44
P/S
2.12
EPS
0.16
Div Yield, %
1.62%
Shrs. gr., 5y
0.51%
Rev. gr., 5y
-7.42%
Revenues
1.53b
-12.09%
Net income
63m
-75.50%
CFO
288m
-27.65%
Dividend
Jun 23, 20250.13487 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Medicalsystem Biotechnology Co., Ltd. is a Chinese company focused on delivering clinical diagnostic solutions. Their comprehensive product line includes a full array of reagents and instruments designed for COVID-19 detection, such as PCR, antibody, and antigen test kits, alongside nucleic acid reagents. Beyond infectious disease diagnostics, the company also supplies advanced medical equipment like automated biochemistry analyzers (complete with their corresponding bio-reagents), hematology analyzers, urine analyzers, and glycated hemoglobin analyzers. Additionally, their offerings extend to Point-of-Care Testing (POCT) devices and cutting-edge chemiluminescence immunoassay analyzers. In addition to its diagnostic product offerings, Medicalsystem also provides healthcare services. Initially established in 2003 as Ningbo Medicalsystem Biotechnology Co., Ltd., the company officially adopted its current name, Medicalsystem Biotechnology Co., Ltd., in January 2017. Its corporate headquarters are situated in Ningbo, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||